Search research articles
Contact Us
Filters
Showing results (301-310 of 333) with videos related to
Page
of 34
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
June 7, 2023
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum
Brian G Weinshenker, Dean M Wingerchuk, Ari J Green, et al.
Annals of Neurology
|
March 19, 2024
Differential Cognitive Effects of Unilateral Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease
Victor A Del Bene, Roy C Martin, Sarah A Brinkerhoff, et al.
Journal of Neurology
|
May 21, 2026
Increased functional network connectivity following cognitive rehabilitation in progressive multiple sclerosis with moderate to severe disabilty: findings from the CogEx study
Francesco Romanò, Paola Valsasina, Matteo Albergoni, et al.
BMC Pediatrics
|
March 25, 2010
Inhaled nitric oxide in preterm infants: a systematic review and individual patient data meta-analysis
Lisa M Askie, Roberta A Ballard, Gary Cutter, et al.
Journal of Neurology
|
November 27, 2022
Structural and functional magnetic resonance imaging correlates of fatigue and dual-task performance in progressive multiple sclerosis
Paolo Preziosa, Maria A Rocca, Elisabetta Pagani, et al.
Ebiomedicine
|
November 12, 2022
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial
Jeffrey L Bennett, Orhan Aktas, William A Rees, et al.
Multiple Sclerosis and Related Disorders
|
February 15, 2022
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder
Romain Marignier, Sean J Pittock, Friedemann Paul, et al.
Therapeutic Advances in Neurological Disorders
|
December 25, 2010
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis
Elliot M Frohman, Gary Cutter, Gina Remington, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
May 16, 2024
Cognitive rehabilitation effects on grey matter volume and Go-NoGo activity in progressive multiple sclerosis: results from the CogEx trial
Maria A Rocca, Paola Valsasina, Francesco Romanò, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
Brian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Page
of 34
Search research articles
Search
Showing results (301-310 of 333) with videos related to
Sort By:
Page
of 34
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
June 7, 2023
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum
Brian G Weinshenker, Dean M Wingerchuk, Ari J Green, et al.
Annals of Neurology
|
March 19, 2024
Differential Cognitive Effects of Unilateral Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease
Victor A Del Bene, Roy C Martin, Sarah A Brinkerhoff, et al.
Journal of Neurology
|
May 21, 2026
Increased functional network connectivity following cognitive rehabilitation in progressive multiple sclerosis with moderate to severe disabilty: findings from the CogEx study
Francesco Romanò, Paola Valsasina, Matteo Albergoni, et al.
BMC Pediatrics
|
March 25, 2010
Inhaled nitric oxide in preterm infants: a systematic review and individual patient data meta-analysis
Lisa M Askie, Roberta A Ballard, Gary Cutter, et al.
Journal of Neurology
|
November 27, 2022
Structural and functional magnetic resonance imaging correlates of fatigue and dual-task performance in progressive multiple sclerosis
Paolo Preziosa, Maria A Rocca, Elisabetta Pagani, et al.
Ebiomedicine
|
November 12, 2022
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial
Jeffrey L Bennett, Orhan Aktas, William A Rees, et al.
Multiple Sclerosis and Related Disorders
|
February 15, 2022
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder
Romain Marignier, Sean J Pittock, Friedemann Paul, et al.
Therapeutic Advances in Neurological Disorders
|
December 25, 2010
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis
Elliot M Frohman, Gary Cutter, Gina Remington, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
May 16, 2024
Cognitive rehabilitation effects on grey matter volume and Go-NoGo activity in progressive multiple sclerosis: results from the CogEx trial
Maria A Rocca, Paola Valsasina, Francesco Romanò, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
Brian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Page
of 34